Interaction Between Mineralocorticoid Receptor Antagonist and Soluble ST2 in Heart Failure with Preserved Ejection Fraction

Background: Soluble ST2 (sST2) is a novel biomarker reflecting myocardial stress and fibrosis. Mineralocorticoid receptor antagonist (MRA) has a potential to improve clinical outcomes in heart failure with preserved ejection fraction (HFpEF), since MRA inhibits progression of myocardial hypertrophy and fibrosis. Aim: To investigate the relationship between sST2 and outcome, and interaction between the effect of MRA and the sST2 level in HFpEF. Methods: 191 patients with acute decompensated HF and EF>50% were prospectively enrolled.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Source Type: research